Jci_page_head_homepage_01 Jci_page_head_homepage_02
Magdalena Juhaszova, Dmitry B. Zorov, Suhn-Hee Kim, Salvatore Pepe, Qin Fu, Kenneth W. Fishbein, Bruce D. Ziman, Su Wang, Kirsti Ytrehus, Christopher L. Antos, Eric N. Olson, Steven J. Sollott
Published in Volume 113, Issue 11
J Clin Invest. 2004; 113(11):1535–1549 doi:10.1172/JCI19906
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2

Change in MPT ROS threshold (tMPT) under reoxygenation and hypoxic and pharmacologic PC. (A) Hypoxia/reoxygenation causes a rapid and progressive decline in tMPT (control, black squares; after reoxygenation, red triangles; O2 in the buffer, blue trace). (B) Hypoxic (HPC) (three 5-minute cycles of hypoxia/reoxygenation) improves tMPT (red triangles compared with control, shown in black squares). (C) Dz pretreatment (30 ∝M for 15 minutes, red bar) prevents the decline in tMPT after hypoxia/reoxygenation. (D) 5HD treatment (500 ∝M, during hypoxic PC phase only, red bar) abolishes the hypoxic PC_mediated protection against the decline in tMPT after hypoxia/reoxygenation. (E) Summary of the effects of hypoxia/reoxygenation and hypoxic and pharmacologic PC on tMPT. *P < 0.01 vs. control (Con). (F) Both cyclosporin A (CSA) (0.2 ∝M) and SFA (1 ∝M) enhance MPT ROS threshold (measured more than 60 minutes after washout). *P < 0.01 vs. control.